PDFPrintEmailAdd to Personalized Information Packet

Life Sciences

We partner with life sciences companies ranging from the producers of some of the world’s best-selling drugs to emerging companies seeking to bring their innovations to market. Whether our clients face a bet-the-company patent dispute, a government investigation or the need to raise capital, we deliver strategic counsel and effective advocacy that enables them to focus on improving patients’ lives.

We work in cross-disciplinary teams to assist our life sciences clients with a wide range of matters, including:

  • Intellectual property, including prosecution and litigation
  • Corporate transactions, including mergers and acquisitions and joint ventures
  • Capital markets transactions, including initial public offerings and private placements
  • Corporate restructuring and financing transactions
  • Securities litigation and government investigations
  • Commercial litigation
  • Corporate compliance programs and internal investigations
  • Advertising litigation
  • Cybersecurity, privacy and data protection
  • Employment law, including executive compensation and employee benefits

Kramer Levin’s Life Sciences IP team combines deep technical and industry knowledge with extensive patent litigation experience to achieve winning results in high-stakes biotechnology, pharmaceutical and medical device patent cases. We represent both emerging and established life sciences companies in patent disputes before the district courts and the Patent Trial and Appeal Board, including in the following areas:

  • Pharmaceuticals (Hatch-Waxman)
  • Biotechnology, biologics and biosimilars
  • Medical devices and diagnostics

In addition to handling big-ticket patent disputes, we work with life sciences clients to maximize protection for their innovations through strategic patent prosecution, as well as advise them on the IP aspects of due diligence, licensing and corporate transactions.

Scotus Expands the Doctrine of Patent Exhaustion to Sales Outside the US and Confirms That the Doctrine Cannot Be Limited Through Post-Sale Restrictions

Learn More

Potential Impact of the Supreme Court’s Decision to Review the PTAB’s Practice of Issuing Partial Final Written Decisions in Post-Grant Proceedings

Learn More